News
-
-
-
PRESS RELEASE
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041, positioning it uniquely and competitively in the treatment landscape -
-
PRESS RELEASE
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
AB Science's patent for masitinib in the treatment of sickle cell disease is formally granted in the United States, providing long-term protection until 2040. The biomarker Phase 2 in cooperation with AP-HP is fully funded -
-
-
-
PRESS RELEASE
AB Science announces the successful completion of a EUR 2.8 million private placement
AB Science successfully completes EUR 2.8 million Private Placement for AB8939 AML program, strengthening cash position for future clinical trials in oncology. Company details expansion phase strategic plan -
